Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Non-alcoholic Fatty Liver Disease in Children

Author(s): Emir Muzurović*, Stergios A. Polyzos, Dimitri P. Mikhailidis, Sanja Borozan, Dušanka Novosel, Oleg Cmiljanić, Nataša Kadić and Christos S. Mantzoros

Volume 21, Issue 1, 2023

Published on: 19 December, 2022

Page: [4 - 25] Pages: 22

DOI: 10.2174/1570161121666221118155136

Price: $65

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in the paediatric age. The growing prevalence of NAFLD and its advanced phenotype, non-alcoholic steatohepatitis (NASH), in children and adolescents parallels similar trends in obesity and type 2 diabetes mellitus. This trend may have serious long-term implications, including hepatic and extra-hepatic morbidity and mortality, the latter being related mostly due to cardiovascular disease and malignancies. This narrative review, which included 236 articles, summarizes current evidence on paediatric NAFLD, including pathophysiology, risk factors, complications, prevention and treatment (existing and emerging). Early recognition of NAFLD followed by timely and adequate management seems to be important on an individual basis. A global “call to action” regarding paediatric NAFLD seems appropriate to mitigate the burden of this disease.

« Previous Next »
Graphical Abstract

[1]
Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the phenotype and approach to pediatric vs. adult patients with nonalcoholic fatty liver disease. Gastroenterology 2016; 150(8): 1798-810.
[http://dx.doi.org/10.1053/j.gastro.2016.03.009] [PMID: 27003600]
[2]
Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 2016; 65(8): 1017-25.
[http://dx.doi.org/10.1016/j.metabol.2016.01.012] [PMID: 26997539]
[3]
Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in Children: Recommendations from the expert committee on NAFLD (ECON) and the North American society of pediatric gastroenterology, hepatology and nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017; 64(2): 319-34.
[http://dx.doi.org/10.1097/MPG.0000000000001482] [PMID: 28107283]
[4]
Fishbein M, Cox S. Non-alcoholic fatty liver disease in a toddler. Clin Pediatr (Phila) 2004; 43(5): 483-5.
[http://dx.doi.org/10.1177/000992280404300512] [PMID: 15208756]
[5]
Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: A follow-up study for up to 20 years. Obes Metab 2010; 7(1): 69-70.
[http://dx.doi.org/10.14341/2071-8713-5285]
[6]
Alisi A, Feldstein AE, Villani A, Raponi M, Nobili V. Pediatric nonalcoholic fatty liver disease: A multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012; 9(3): 152-61.
[http://dx.doi.org/10.1038/nrgastro.2011.273] [PMID: 22249728]
[7]
Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N. NAFLD in children: New genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol 2019; 16(9): 517-30.
[http://dx.doi.org/10.1038/s41575-019-0169-z] [PMID: 31278377]
[8]
Nobili V, Mantovani A, Cianfarani S, et al. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. J Hepatol 2019; 71(4): 802-10.
[http://dx.doi.org/10.1016/j.jhep.2019.06.023] [PMID: 31279904]
[9]
Selvakumar PKC, Kabbany MN, Nobili V, Alkhouri N. Nonalcoholic fatty liver disease in children. Pediatr Clin North Am 2017; 64(3): 659-75.
[http://dx.doi.org/10.1016/j.pcl.2017.01.008] [PMID: 28502444]
[10]
Polyzos SA, Kountouras J, Mantzoros CS. Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol 2017; 42(2): 92-108.
[PMID: 27711029]
[11]
Goyal NP, Schwimmer JB. The genetics of pediatric nonalcoholic fatty liver disease. Clin Liver Dis 2018; 22(1): 59-71.
[http://dx.doi.org/10.1016/j.cld.2017.08.002] [PMID: 29128061]
[12]
Kanwal F, Shubrook JH, Younossi Z, et al. Preparing for the NASH epidemic: A call to action. Metabolism 2021; 122: 154822.
[http://dx.doi.org/10.1016/j.metabol.2021.154822] [PMID: 34289945]
[13]
Polyzos SA, Mantzoros CS. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 2014; 63(2): 161-7.
[http://dx.doi.org/10.1016/j.metabol.2013.10.010] [PMID: 24290839]
[14]
Alkhouri N, De Vito R, Alisi A, et al. Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. J Hepatol 2012; 57(6): 1312-8.
[http://dx.doi.org/10.1016/j.jhep.2012.07.027] [PMID: 22871498]
[15]
Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118(4): 1388-93.
[http://dx.doi.org/10.1542/peds.2006-1212] [PMID: 17015527]
[16]
Mencin AA, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Pediatr Clin North Am 2011; 58(6): 1375-92. x.
[http://dx.doi.org/10.1016/j.pcl.2011.09.005] [PMID: 22093857]
[17]
Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7(2): 234-8.
[http://dx.doi.org/10.1016/j.cgh.2008.11.005] [PMID: 19049831]
[18]
Mansoor S, Yerian L, Kohli R, et al. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease. Dig Dis Sci 2015; 60(5): 1440-7.
[http://dx.doi.org/10.1007/s10620-014-3494-7] [PMID: 25540086]
[19]
Carter-Kent C, Brunt EM, Yerian LM, et al. Relations of steatosis type, grade, and zonality to histological features in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2011; 52(2): 190-7.
[http://dx.doi.org/10.1097/MPG.0b013e3181fb47d3] [PMID: 21240012]
[20]
Goyal NP, Schwimmer JB. The progression and natural history of pediatric nonalcoholic fatty liver disease. Clin Liver Dis 2016; 20(2): 325-38.
[http://dx.doi.org/10.1016/j.cld.2015.10.003] [PMID: 27063272]
[21]
Alkhouri N, Sedki E, Alisi A, et al. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver Int 2013; 33(1): 79-85.
[http://dx.doi.org/10.1111/liv.12024] [PMID: 23146095]
[22]
Akader H, Henderson J, Vanhoesen K, Ghishan F, Bhattacharyya A. Nonalcoholic fatty liver disease in children: A single center experience. Clin Gastroenterol Hepatol 2008; 6(7): 799-802.
[http://dx.doi.org/10.1016/j.cgh.2008.03.001]
[23]
Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: A follow-up study for up to 20 years. Gut 2009; 58(11): 1538-44.
[http://dx.doi.org/10.1136/gut.2008.171280] [PMID: 19625277]
[24]
Doulberis M, Polyzos SA, Papaefthymiou A, Katsinelos P, Kiosses C, Kountouras J. Treatment of nonalcoholic fatty liver disease: From adult trials to perspectives in the management of children and adolescents. Expert Opin Pharmacother 2020; 21(3): 247-51.
[http://dx.doi.org/10.1080/14656566.2019.1702967] [PMID: 31893958]
[25]
Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: Multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 2012; 46(4): 272-84.
[http://dx.doi.org/10.1097/MCG.0b013e31824587e0] [PMID: 22395062]
[26]
Wong RJ, Singal AK. Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019. JAMA Netw Open 2020; 3(2): e1920294.
[http://dx.doi.org/10.1001/jamanetworkopen.2019.20294] [PMID: 32022875]
[27]
Alkhouri N, Hanouneh IA, Zein NN, et al. Liver transplantation for nonalcoholic steatohepatitis in young patients. Transpl Int 2016; 29(4): 418-24.
[http://dx.doi.org/10.1111/tri.12694] [PMID: 26402655]
[28]
Nobili V, Alisi A, Grimaldi C, et al. Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: Coincidence or comorbidity? Pediatr Obes 2014; 9(5): e99-e102.
[http://dx.doi.org/10.1111/j.2047-6310.2013.00209.x] [PMID: 24302697]
[29]
Patton HM, Yates K, Unalp-Arida A, et al. Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease. Am J Gastroenterol 2010; 105(9): 2093-102.
[http://dx.doi.org/10.1038/ajg.2010.152] [PMID: 20372110]
[30]
Manco M, Marcellini M, DeVito R, Comparcola D, Sartorelli MR, Nobili V. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes 2008; 32(2): 381-7.
[http://dx.doi.org/10.1038/sj.ijo.0803711] [PMID: 18087267]
[31]
Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr 2003; 143(4): 500-5.
[http://dx.doi.org/10.1067/S0022-3476(03)00325-1] [PMID: 14571229]
[32]
Tritos NA, Mantzoros CS. Clinical review 97: Syndromes of severe insulin resistance. J Clin Endocrinol Metab 1998; 83(9): 3025-30.
[http://dx.doi.org/10.1210/jcem.83.9.5143] [PMID: 9745395]
[33]
Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation 2008; 118(3): 277-83.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.739920] [PMID: 18591439]
[34]
Katsiki N, Athyros VG, Mikhailidis DP. Abnormal peri-organ or intra-organ fat (apifat) deposition: An underestimated predictor of vascular risk? Curr Vasc Pharmacol 2016; 14(5): 432-41.
[http://dx.doi.org/10.2174/1570161114666160722112738] [PMID: 27456108]
[35]
Muzurović EM, Vujošević S, Mikhailidis DP. Can we decrease epicardial and pericardial fat in patients with diabetes? J Cardiovasc Pharmacol Ther 2021; 26(5): 415-36.
[http://dx.doi.org/10.1177/10742484211006997] [PMID: 33844605]
[36]
Muzurović E, Cojić M, Stanković Z, Janež A. Epicardial adipocyte-derived TNF-α modulates local inflammation in patients with advanced coronary artery disease. Curr Vasc Pharmacol 2022; 20(1): 94-5.
[http://dx.doi.org/10.2174/157016112001211228145754] [PMID: 35040396]
[37]
Akkurt MO, Turan OM, Crimmins S, Harman CR, Turan S. Increased fetal epicardial fat thickness: A novel ultrasound marker for altered fetal metabolism in diabetic pregnancies. J Clin Ultrasound 2018; 46(6): 397-402.
[http://dx.doi.org/10.1002/jcu.22602] [PMID: 29740837]
[38]
Alp H, Karaarslan S. Selver Eklioğlu B, Atabek ME, Altın H, Baysal T. Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. Can J Cardiol 2013; 29(9): 1118-25.
[http://dx.doi.org/10.1016/j.cjca.2012.07.846] [PMID: 23040432]
[39]
Newton KP, Hou J, Crimmins NA, et al. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr 2016; 170(10): e161971.
[http://dx.doi.org/10.1001/jamapediatrics.2016.1971] [PMID: 27478956]
[40]
Caprio S, Perry R, Kursawe R. Adolescent obesity and insulin resistance: Roles of ectopic fat accumulation and adipose inflammation. Gastroenterology 2017; 152(7): 1638-46.
[http://dx.doi.org/10.1053/j.gastro.2016.12.051] [PMID: 28192105]
[41]
Cioffi CE, Welsh JA, Cleeton RL, et al. Natural history of NAFLD diagnosed in childhood: A single-center study. Children (Basel) 2017; 4(5): 34.
[http://dx.doi.org/10.3390/children4050034] [PMID: 28467377]
[42]
Wlazlo N, Beijers HJBH, Schoon EJ, Sauerwein HP, Stehouwer CDA, Bravenboer B. High prevalence of diabetes mellitus in patients with liver cirrhosis. Diabet Med 2010; 27(11): 1308-11.
[http://dx.doi.org/10.1111/j.1464-5491.2010.03093.x] [PMID: 20968111]
[43]
Nobili V, Alkhouri N, Bartuli A, et al. Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr Res 2010; 67(6): 665-70.
[http://dx.doi.org/10.1203/PDR.0b013e3181da4798] [PMID: 20496475]
[44]
Corey KE, Vuppalanchi R, Vos M, et al. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2015; 60(3): 360-7.
[http://dx.doi.org/10.1097/MPG.0000000000000584] [PMID: 25714579]
[45]
Schwimmer JB, Zepeda A, Newton KP, et al. Longitudinal assessment of high blood pressure in children with nonalcoholic fatty liver disease. PLoS One 2014; 9(11): e112569.
[http://dx.doi.org/10.1371/journal.pone.0112569] [PMID: 25419656]
[46]
Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 2021; 119: 154770.
[http://dx.doi.org/10.1016/j.metabol.2021.154770] [PMID: 33864798]
[47]
Di Sessa A, Umano GR, Miraglia del Giudice E, Santoro N. From the liver to the heart: Cardiac dysfunction in obese children with non-alcoholic fatty liver disease. World J Hepatol 2017; 9(2): 69-73.
[http://dx.doi.org/10.4254/wjh.v9.i2.69] [PMID: 28144387]
[48]
Caserta CA, Pendino GM, Alicante S, et al. Body mass index, cardiovascular risk factors, and carotid intima-media thickness in a pediatric population in southern Italy. J Pediatr Gastroenterol Nutr 2010; 51(2): 216-20.
[http://dx.doi.org/10.1097/MPG.0b013e3181d4c21d] [PMID: 20512056]
[49]
Demircioğlu F, Koçyiğit A, Arslan N, Çakmakç H, Hzl Ş Sedat AT. Intima-media thickness of carotid artery and susceptibility to atherosclerosis in obese children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2008; 47(1): 68-75.
[http://dx.doi.org/10.1097/MPG.0b013e31816232c9] [PMID: 18607271]
[50]
Pacifico L, Cantisani V, Ricci P, et al. Nonalcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res 2008; 63(4): 423-7.
[http://dx.doi.org/10.1203/PDR.0b013e318165b8e7] [PMID: 18356751]
[51]
Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. Gut 2022; 71(9): 1867-75.
[52]
Kaur H, Premkumar M. Diagnosis and management of cirrhotic cardiomyopathy. J Clin Exp Hepatol 2022; 12(1): 186-99.
[http://dx.doi.org/10.1016/j.jceh.2021.08.016] [PMID: 35068798]
[53]
Muzurović E, Peng CCH, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic fatty liver disease and cardiovascular disease: A review of shared cardiometabolic risk factors. Hypertension 2022; 79(7): 1319-26.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.122.17982] [PMID: 35465684]
[54]
Eslam M, George J. Genetic and epigenetic mechanisms of NASH. Hepatol Int 2016; 10(3): 394-406.
[http://dx.doi.org/10.1007/s12072-015-9689-y] [PMID: 26683320]
[55]
Liu Z, Suo C, Shi O, et al. The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease–related genetic variants. Clin Gastroenterol Hepatol 2022; 20(4): e855-75.
[http://dx.doi.org/10.1016/j.cgh.2020.12.033] [PMID: 33387670]
[56]
Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65(8): 1038-48.
[http://dx.doi.org/10.1016/j.metabol.2015.12.012] [PMID: 26823198]
[57]
Goldner D, Lavine JE. Nonalcoholic fatty liver disease in children: Unique considerations and challenges. Gastroenterology 2020; 158(7): 1967-1983.e1.
[http://dx.doi.org/10.1053/j.gastro.2020.01.048] [PMID: 32201176]
[58]
Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: Insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001; 96(10): 2957-61.
[http://dx.doi.org/10.1111/j.1572-0241.2001.04667.x] [PMID: 11693332]
[59]
Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40(6): 1387-95.
[http://dx.doi.org/10.1002/hep.20466] [PMID: 15565570]
[60]
Makkonen J, Pietiläinen KH, Rissanen A, Kaprio J, Yki-Järvinen H. Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: A study in monozygotic and dizygotic twins. J Hepatol 2009; 50(5): 1035-42.
[http://dx.doi.org/10.1016/j.jhep.2008.12.025] [PMID: 19303161]
[61]
Loomba R, Rao F, Zhang L, et al. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology 2010; 139(3): 836-845.e1, 845.e1..
[http://dx.doi.org/10.1053/j.gastro.2010.06.009] [PMID: 20537997]
[62]
Sookoian S, Pirola C. Genetics of nonalcoholic fatty liver disease: From pathogenesis to therapeutics. Semin Liver Dis 2019; 39(2): 124-40.
[http://dx.doi.org/10.1055/s-0039-1679920] [PMID: 30912099]
[63]
Townsend SA, Newsome PN. New treatments in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017; 46(5): 494-507.
[http://dx.doi.org/10.1111/apt.14210] [PMID: 28677333]
[64]
Polyzos SA, Bugianesi E, Kountouras J, Mantzoros CS. Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists. Metabolism 2017; 66: 64-8.
[http://dx.doi.org/10.1016/j.metabol.2016.08.001] [PMID: 27594084]
[65]
Lazo M, Bilal U, Mitchell MC, Potter J, Hernaez R, Clark JM. Interaction between alcohol consumption and pnpla3 variant in the prevalence of hepatic steatosis in the US population. Clin Gastroenterol Hepatol 2021; 19(12): 2606-2614.e4.
[http://dx.doi.org/10.1016/j.cgh.2020.08.054] [PMID: 32882427]
[66]
Romeo S, Sentinelli F, Cambuli VM, et al. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010; 53(2): 335-8.
[http://dx.doi.org/10.1016/j.jhep.2010.02.034] [PMID: 20546964]
[67]
Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40(12): 1461-5.
[http://dx.doi.org/10.1038/ng.257] [PMID: 18820647]
[68]
Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem 2011; 286(43): 37085-93.
[http://dx.doi.org/10.1074/jbc.M111.290114] [PMID: 21878620]
[69]
He S, McPhaul C, Li JZ, et al. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285(9): 6706-15.
[http://dx.doi.org/10.1074/jbc.M109.064501] [PMID: 20034933]
[70]
Winberg ME, Khalaj Motlagh M, Stenkula KG, Holm C, Jones HA. Adiponutrin: A multimeric plasma protein. Biochem Biophys Res Commun 2014; 446(4): 1114-9.
[http://dx.doi.org/10.1016/j.bbrc.2014.03.078] [PMID: 24680680]
[71]
Vespasiani-Gentilucci U, Gallo P, Porcari A, et al. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scand J Gastroenterol 2016; 51(8): 967-73.
[http://dx.doi.org/10.3109/00365521.2016.1161066] [PMID: 27150500]
[72]
Liu YL, Patman GL, Leathart JBS, et al. Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014; 61(1): 75-81.
[http://dx.doi.org/10.1016/j.jhep.2014.02.030] [PMID: 24607626]
[73]
Tepper CG, Dang JHT, Stewart SL, et al. High frequency of the PNPLA3 rs738409 [G] single-nucleotide polymorphism in Hmong individuals as a potential basis for a predisposition to chronic liver disease. Cancer 2018; 124 (Suppl. 7): 1583-9.
[http://dx.doi.org/10.1002/cncr.31122] [PMID: 29578593]
[74]
Santoro N, Kursawe R, D’Adamo E, et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010; 52(4): 1281-90.
[http://dx.doi.org/10.1002/hep.23832] [PMID: 20803499]
[75]
Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014; 46(4): 352-6.
[http://dx.doi.org/10.1038/ng.2901] [PMID: 24531328]
[76]
Míková I. , Neřoldová M, Hubáček JA, et al. Donor PNPLA3 and TM6SF2 variant alleles confer additive risks for graft steatosis after liver transplantation. Transplantation 2020; 104(3): 526-34.
[http://dx.doi.org/10.1097/TP.0000000000002876] [PMID: 31356578]
[77]
Goffredo M, Caprio S, Feldstein AE, et al. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. Hepatology 2016; 63(1): 117-25.
[http://dx.doi.org/10.1002/hep.28283] [PMID: 26457389]
[78]
Grandone A, Cozzolino D, Marzuillo P, et al. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children. Pediatr Obes 2016; 11(2): 115-9.
[http://dx.doi.org/10.1111/ijpo.12032] [PMID: 25893821]
[79]
Viitasalo A, Pihlajamäki J, Paananen J, Atalay M, Lindi V, Lakka TA. Associations of TM6SF2 167K allele with liver enzymes and lipid profile in children: the PANIC Study. Pediatr Res 2016; 79(5): 684-8.
[http://dx.doi.org/10.1038/pr.2016.3] [PMID: 26756786]
[80]
Käräjämäki AJ, Hukkanen J, Kauma H, Kesäniemi YA, Ukkola O. Metabolic syndrome but not genetic polymorphisms known to induce NAFLD predicts increased total mortality in subjects with NAFLD (OPERA study). Scand J Clin Lab Invest 2020; 80(2): 106-13.
[http://dx.doi.org/10.1080/00365513.2019.1700428] [PMID: 31851849]
[81]
Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021; 54(8): 1013-25.
[http://dx.doi.org/10.1111/apt.16575] [PMID: 34416040]
[82]
Lee KJ, Moon JS, Kim NY, Ko JS. Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non‐alcoholic fatty liver disease in children. Pediatr Obes 2022; 17(2): e12852.
[http://dx.doi.org/10.1111/ijpo.12852] [PMID: 34490745]
[83]
Wang X, Liu Z, Wang K, et al. Additive effects of the risk alleles of PNPLA3 and TM6SF2 on non-alcoholic fatty liver disease (NAFLD) in a Chinese population. Front Genet 2016; 7: 140.
[http://dx.doi.org/10.3389/fgene.2016.00140] [PMID: 27532011]
[84]
Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun 2014; 5(1): 4309.
[http://dx.doi.org/10.1038/ncomms5309] [PMID: 24978903]
[85]
Bing H, Wang W, Li YL. Correlation between PNPLA3 rs738409 and TM6SF2 rs58542926 gene polymorphism and primary liver cancer in the Han population of China’s Northeast region. Clin J Hepatol 2021; 29(2): 156-62.
[PMID: 33685085]
[86]
Koo BK, Joo SK, Kim D, et al. Development and validation of a scoring system, based on genetic and clinical factors, to determine risk of steatohepatitis in Asian patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2020; 18(11): 2592-2599.e10.
[http://dx.doi.org/10.1016/j.cgh.2020.02.011] [PMID: 32062042]
[87]
Luukkonen PK, Zhou Y, Hyötyläinen T, et al. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans. J Hepatol 2016; 65(6): 1263-5.
[http://dx.doi.org/10.1016/j.jhep.2016.07.045] [PMID: 27520876]
[88]
Mancina RM, Dongiovanni P, Petta S, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 2016; 150(5): 1219-1230.e6.
[http://dx.doi.org/10.1053/j.gastro.2016.01.032] [PMID: 26850495]
[89]
Di Sessa A, Umano GR, Cirillo G, et al. The membrane-bound o-acyltransferase7 rs641738 variant in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2018; 67(1): 69-74.
[http://dx.doi.org/10.1097/MPG.0000000000001979] [PMID: 29601441]
[90]
Umano GR, Caprio S, Di Sessa A, et al. The rs626283 variant in the MBOAT7 gene is associated with insulin resistance and fatty liver in caucasian obese youth. Am J Gastroenterol 2018; 113(3): 376-83.
[http://dx.doi.org/10.1038/ajg.2018.1] [PMID: 29485130]
[91]
Zusi C, Morandi A, Maguolo A, et al. Association between MBOAT7 rs641738 polymorphism and non-alcoholic fatty liver in overweight or obese children. Nutr Metab Cardiovasc Dis 2021; 31(5): 1548-55.
[http://dx.doi.org/10.1016/j.numecd.2021.01.020] [PMID: 33810963]
[92]
Santoro N, Zhang CK, Zhao H, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2012; 55(3): 781-9.
[http://dx.doi.org/10.1002/hep.24806] [PMID: 22105854]
[93]
Petta S, Miele L, Bugianesi E, et al. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS One 2014; 9(2): e87523.
[http://dx.doi.org/10.1371/journal.pone.0087523] [PMID: 24498332]
[94]
Zain SM, Mohamed Z, Mohamed R. A common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: A meta-analysis. J Gastroenterol Hepatol 2015; 30(1): 21-7.
[http://dx.doi.org/10.1111/jgh.12714] [PMID: 25167786]
[95]
Abul-Husn NS, Cheng X, Li AH, et al. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J Med 2018; 378(12): 1096-106.
[http://dx.doi.org/10.1056/NEJMoa1712191] [PMID: 29562163]
[96]
Kumari M, Schoiswohl G, Chitraju C, et al. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab 2012; 15(5): 691-702.
[http://dx.doi.org/10.1016/j.cmet.2012.04.008] [PMID: 22560221]
[97]
Vespasiani-Gentilucci U, Dell’Unto C, De Vincentis A, et al. Combining genetic variants to improve risk prediction for NAFLD and its progression to cirrhosis: A proof of concept study. Can J Gastroenterol Hepatol 2018; 2018: 7564835.
[http://dx.doi.org/10.1155/2018/7564835] [PMID: 29732362]
[98]
Valenti L, Motta BM, Alisi A, et al. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2012; 54(5): 588-93.
[http://dx.doi.org/10.1097/MPG.0b013e3182442a55] [PMID: 22157924]
[99]
Sfikas G, Psallas M, Koumaras C, et al. Prevalence, diagnosis, and treatment with 3 different statins of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in military personnel. Do genetics play a role? Curr Vasc Pharmacol 2021; 19(5): 572-81.
[http://dx.doi.org/10.2174/1570161118666201015152921] [PMID: 33059580]
[100]
Muzurović E, Smolović B, Vujošević S, Petakov M. Editorial on prevalence, diagnosis and treatment with 3 different statins of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in military personnel. Do genetics play a role? Curr Vasc Pharmacol 2021; 19(5): 582-4.
[http://dx.doi.org/10.2174/1570161118666201008162537] [PMID: 33032512]
[101]
Valenzuela FJ, Vera J, Venegas C, et al. Evidences of polymorphism associated with circadian system and risk of pathologies: A review of the literature. Int J Endocrinol 2016; 2016: 2746909.
[http://dx.doi.org/10.1155/2016/2746909] [PMID: 27313610]
[102]
Gómez R. The role of population genetics and its implications in the study of complex-Disease risk. J Genet Mol Biol 2017; 1(1): 12-3.
[http://dx.doi.org/10.35841/genetics-molecular-biology.1.1.12-13]
[103]
Younes R, Bugianesi E. NASH in lean individuals. Semin Liver Dis 2019; 39(1): 086-95.
[http://dx.doi.org/10.1055/s-0038-1677517] [PMID: 30654392]
[104]
Das K, Chowdhury A. Lean NASH: distinctiveness and clinical implication. Hepatol Int 2013; 7 (Suppl. 2): 806-13.
[http://dx.doi.org/10.1007/s12072-013-9477-5] [PMID: 26202295]
[105]
Wong VWS, Wong GLH, Yeung DKW, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. J Hepatol 2015; 62(1): 182-9.
[http://dx.doi.org/10.1016/j.jhep.2014.08.041] [PMID: 25195550]
[106]
Nobili V, Donati B, Panera N, et al. A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2014; 58(5): 632-6.
[http://dx.doi.org/10.1097/MPG.0000000000000279] [PMID: 24345846]
[107]
Manti S, Romano C, Chirico V, et al. Nonalcoholic fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic “mal-programming”. Hepat Mon 2014; 14(4): e17641.
[http://dx.doi.org/10.5812/hepatmon.17641] [PMID: 24829591]
[108]
Giorgio V, Prono F, Graziano F, Nobili V. Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatr 2013; 13(1): 40.
[http://dx.doi.org/10.1186/1471-2431-13-40] [PMID: 23530957]
[109]
Mann J, Valenti L, Scorletti E, Byrne C, Nobili V. Nonalcoholic fatty liver disease in children. Semin Liver Dis 2018; 38: 1-13.
[http://dx.doi.org/10.1055/s-0038-1627456]
[110]
Brumbaugh DE, Tearse P, Cree-Green M, et al. Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes. J Pediatr 2013; 162(5): 930-936.e1.
[http://dx.doi.org/10.1016/j.jpeds.2012.11.017] [PMID: 23260099]
[111]
Modi N, Murgasova D, Ruager-Martin R, et al. The influence of maternal body mass index on infant adiposity and hepatic lipid content. Pediatr Res 2011; 70(3): 287-91.
[http://dx.doi.org/10.1203/PDR.0b013e318225f9b1] [PMID: 21629154]
[112]
Vos MB. Furthering the understanding of maternal obesity in nonalcoholic fatty liver disease. Hepatology 2013; 58(1): 4-5.
[http://dx.doi.org/10.1002/hep.26389] [PMID: 23504746]
[113]
Knorr S, Bytoft B, Lohse Z, et al. Fatty liver among adolescent offspring of women with type 1 diabetes (the EPICOM Study). Diabetes Care 2019; 42(8): 1560-8.
[http://dx.doi.org/10.2337/dc19-0571] [PMID: 31167890]
[114]
Li M, Reynolds CM, Segovia SA, Gray C, Vickers MH. Developmental programming of nonalcoholic fatty liver disease: the effect of early life nutrition on susceptibility and disease severity in later life. BioMed Res Int 2015; 2015: 437107.
[http://dx.doi.org/10.1155/2015/437107] [PMID: 26090409]
[115]
Thorn SR, Baquero KC, Newsom SA, et al. Early life exposure to maternal insulin resistance has persistent effects on hepatic NAFLD in juvenile nonhuman primates. Diabetes 2014; 63(8): 2702-13.
[http://dx.doi.org/10.2337/db14-0276] [PMID: 24705404]
[116]
Bush NC, Chandler-Laney PC, Rouse DJ, Granger WM, Oster RA, Gower BA. Higher maternal gestational glucose concentration is associated with lower offspring insulin sensitivity and altered beta-cell function. J Clin Endocrinol Metab 2011; 96(5): E803-9.
[http://dx.doi.org/10.1210/jc.2010-2902] [PMID: 21346075]
[117]
Vlachová Z, Bytoft B, Knorr S, et al. Increased metabolic risk in adolescent offspring of mothers with type 1 diabetes: the EPICOM study. Diabetologia 2015; 58(7): 1454-63.
[http://dx.doi.org/10.1007/s00125-015-3589-5] [PMID: 25924986]
[118]
Patel KR, White FV, Deutsch GH. Hepatic steatosis is prevalent in stillborns delivered to women with diabetes mellitus. J Pediatr Gastroenterol Nutr 2015; 60(2): 152-8.
[http://dx.doi.org/10.1097/MPG.0000000000000520] [PMID: 25079479]
[119]
Suomela E, Oikonen M, Pitkänen N, et al. Childhood predictors of adult fatty liver. The cardiovascular risk in young finns study. J Hepatol 2016; 65(4): 784-90.
[http://dx.doi.org/10.1016/j.jhep.2016.05.020] [PMID: 27235307]
[120]
Sandboge S, Perälä MM, Salonen MK, et al. Early growth and non-alcoholic fatty liver disease in adulthood—the NAFLD liver fat score and equation applied on the Helsinki Birth Cohort Study. Ann Med 2013; 45(5-6): 430-7.
[http://dx.doi.org/10.3109/07853890.2013.801275] [PMID: 23767967]
[121]
Nobili V, Marcellini M, Marchesini G, et al. Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. Diabetes Care 2007; 30(10): 2638-40.
[http://dx.doi.org/10.2337/dc07-0281] [PMID: 17536073]
[122]
Bugianesi E, Bizzarri C, Rosso C, et al. Low birthweight increases the likelihood of severe steatosis in pediatric non-alcoholic fatty liver disease. Am J Gastroenterol 2017; 112(8): 1277-86.
[http://dx.doi.org/10.1038/ajg.2017.140] [PMID: 28555633]
[123]
McCurdy CE, Bishop JM, Williams SM, et al. Maternal high-fat diet triggers lipotoxicity in the fetal livers of nonhuman primates. J Clin Invest 2009; 119(2): 323-35.
[http://dx.doi.org/10.1172/JCI32661] [PMID: 19147984]
[124]
Li J, Huang J, Li JS, Chen H, Huang K, Zheng L. Accumulation of endoplasmic reticulum stress and lipogenesis in the liver through generational effects of high fat diets. J Hepatol 2012; 56(4): 900-7.
[http://dx.doi.org/10.1016/j.jhep.2011.10.018] [PMID: 22173165]
[125]
Takasaki M, Honma T, Yanaka M, et al. Continuous intake of a high-fat diet beyond one generation promotes lipid accumulation in liver and white adipose tissue of female mice. J Nutr Biochem 2012; 23(6): 640-5.
[http://dx.doi.org/10.1016/j.jnutbio.2011.03.008] [PMID: 21775120]
[126]
Kruse M, Seki Y, Vuguin PM, et al. High-fat intake during pregnancy and lactation exacerbates high-fat diet-induced complications in male offspring in mice. Endocrinology 2013; 154(10): 3565-76.
[http://dx.doi.org/10.1210/en.2012-1877] [PMID: 23861375]
[127]
Patel S, Lawlor DA, Callaway M, Macdonald-Wallis C, Sattar N, Fraser A. Association of maternal diabetes/glycosuria and pre-pregnancy body mass index with offspring indicators of non-alcoholic fatty liver disease. BMC Pediatr 2016; 16(1): 47.
[http://dx.doi.org/10.1186/s12887-016-0585-y] [PMID: 27036545]
[128]
Bellatorre A, Scherzinger A, Stamm E, Martinez M, Ringham B, Dabelea D. Fetal overnutrition and adolescent hepatic fat fraction: the exploring perinatal outcomes in children study. J Pediatr 2018; 192: 165-170.e1.
[http://dx.doi.org/10.1016/j.jpeds.2017.09.008] [PMID: 29046229]
[129]
Foulds CE, Treviño LS, York B, Walker CL. Endocrine-disrupting chemicals and fatty liver disease. Nat Rev Endocrinol 2017; 13(8): 445-57.
[http://dx.doi.org/10.1038/nrendo.2017.42] [PMID: 28524171]
[130]
Polyzos SA, Kountouras J, Deretzi G, Zavos C, Mantzoros CS. The emerging role of endocrine disruptors in pathogenesis of insulin resistance: A concept implicating nonalcoholic fatty liver disease. Curr Mol Med 2012; 12(1): 68-82.
[http://dx.doi.org/10.2174/156652412798376161] [PMID: 22082482]
[131]
Breij LM, Kerkhof GF, Hokken-Koelega ACS. Accelerated infant weight gain and risk for nonalcoholic fatty liver disease in early adulthood. J Clin Endocrinol Metab 2014; 99(4): 1189-95.
[http://dx.doi.org/10.1210/jc.2013-3199] [PMID: 24423333]
[132]
Ayonrinde OT, Oddy WH, Adams LA, et al. Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents. J Hepatol 2017; 67(3): 568-76.
[http://dx.doi.org/10.1016/j.jhep.2017.03.029] [PMID: 28619255]
[133]
Soderborg TK, Clark SE, Mulligan CE, et al. The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD. Nat Commun 2018; 9(1): 4462.
[http://dx.doi.org/10.1038/s41467-018-06929-0] [PMID: 30367045]
[134]
Dongiovanni P, Lanti C, Riso P, Valenti L. Nutritional therapy for nonalcoholic fatty liver disease. J Nutr Biochem 2016; 29: 1-11.
[http://dx.doi.org/10.1016/j.jnutbio.2015.08.024] [PMID: 26895659]
[135]
Rani MA, Sathiyasekaran BWC. Behavioural determinants for obesity: a cross-sectional study among urban adolescents in India. J Prev Med Public Health 2013; 46(4): 192-200.
[http://dx.doi.org/10.3961/jpmph.2013.46.4.192] [PMID: 23946877]
[136]
Vachliotis I, Goulas A, Papaioannidou P, Polyzos SA. Nonalcoholic fatty liver disease: lifestyle and quality of life. Hormones (Athens) 2022; 21(1): 41-9.
[http://dx.doi.org/10.1007/s42000-021-00339-6] [PMID: 34854066]
[137]
Kim CH, Kallman JB, Bai C, et al. Nutritional assessments of patients with non-alcoholic fatty liver disease. Obes Surg 2010; 20(2): 154-60.
[http://dx.doi.org/10.1007/s11695-008-9549-0] [PMID: 18560947]
[138]
Seidelmann SB, Claggett B, Cheng S, et al. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. Lancet Public Health 2018; 3(9): e419-28.
[http://dx.doi.org/10.1016/S2468-2667(18)30135-X] [PMID: 30122560]
[139]
Neumark-Sztainer D, Story M, Resnick MD, Blum RW. Correlates of inadequate fruit and vegetable consumption among adolescents. Prev Med 1996; 25(5): 497-505.
[http://dx.doi.org/10.1006/pmed.1996.0082] [PMID: 8888316]
[140]
Robinson TN. Reducing children’s television viewing to prevent obesity: A randomized controlled trial. JAMA 1999; 282(16): 1561-7.
[http://dx.doi.org/10.1001/jama.282.16.1561] [PMID: 10546696]
[141]
Kansra AR, Lakkunarajah S, Jay MS. Childhood and adolescent obesity: A review. Front Pediatr 2021; 8: 581461.
[http://dx.doi.org/10.3389/fped.2020.581461] [PMID: 33511092]
[142]
Ozhan B, Ersoy B, Kiremitci S, Ozkol M, Taneli F. Insulin sensitivity indices: fasting versus glucose-stimulated ındices in pediatric non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci 2015; 19(18): 3450-8.
[PMID: 26439042]
[143]
Anderson EL, Howe LD, Jones HE, Higgins JPT, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: A systematic review and meta-analysis. PLoS One 2015; 10(10): e0140908.
[http://dx.doi.org/10.1371/journal.pone.0140908] [PMID: 26512983]
[144]
Silveira LS, Monteiro PA, Antunes BMM, et al. Intra-abdominal fat is related to metabolic syndrome and non-alcoholic fat liver disease in obese youth. BMC Pediatr 2013; 13(1): 115.
[http://dx.doi.org/10.1186/1471-2431-13-115] [PMID: 23919592]
[145]
Monteiro PA, de Moura Mello Antunes B, Silveira LS, Christofaro DGD, Fernandes RA, Freitas IF. Body composition variables as predictors of NAFLD by ultrasound in obese children and adolescents. BMC Pediatr 2014; 14(1): 25.
[http://dx.doi.org/10.1186/1471-2431-14-25] [PMID: 24476029]
[146]
Ko YH, Wong TC, Hsu YY, Kuo KL, Yang SH. The correlation between body fat, visceral fat, and nonalcoholic fatty liver disease. Metab Syndr Relat Disord 2017; 15(6): 304-11.
[http://dx.doi.org/10.1089/met.2017.0001] [PMID: 28481662]
[147]
Lee JY, Kim KM, Lee SG, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: A review of 589 consecutive liver biopsies in a single center. J Hepatol 2007; 47(2): 239-44.
[http://dx.doi.org/10.1016/j.jhep.2007.02.007] [PMID: 17400323]
[148]
Omagari K, Kadokawa Y, Masuda JI, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: Incidence and clinical characteristics. J Gastroenterol Hepatol 2002; 17(10): 1098-105.
[http://dx.doi.org/10.1046/j.1440-1746.2002.02846.x] [PMID: 12201871]
[149]
Mathew H, Farr OM, Mantzoros CS. Metabolic health and weight: Understanding metabolically unhealthy normal weight or metabolically healthy obese patients. Metabolism 2016; 65(1): 73-80.
[http://dx.doi.org/10.1016/j.metabol.2015.10.019] [PMID: 26683798]
[150]
Muzurović E, Stanković Z, Kovačević Z, Škrijelj BŠ, Mikhailidis DP. Inflammatory markers associated with diabetes mellitus – old and new players. Curr Pharm Des 2021; 27(27): 3020-35.
[http://dx.doi.org/10.2174/1381612826666201125103047] [PMID: 33238871]
[151]
Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016; 65(8): 1062-79.
[http://dx.doi.org/10.1016/j.metabol.2015.11.006] [PMID: 26725002]
[152]
Barb D, Pazaitou-Panayiotou K, Mantzoros CS. Adiponectin: a link between obesity and cancer. Expert Opin Investig Drugs 2006; 15(8): 917-31.
[http://dx.doi.org/10.1517/13543784.15.8.917] [PMID: 16859394]
[153]
Polyzos S, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009; 9(3): 299-314.
[http://dx.doi.org/10.2174/156652409787847191] [PMID: 19355912]
[154]
Goyale A, Jain A, Smith C, et al. Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. PLoS One 2021; 16(11): e0260313.
[http://dx.doi.org/10.1371/journal.pone.0260313] [PMID: 34813621]
[155]
Shah J, Okubote T, Alkhouri N. Overview of updated practice guidelines for pediatric nonalcoholic fatty liver disease. Gastroenterol Hepatol (N Y) 2018; 14(7): 407-14.
[PMID: 30166956]
[156]
Muzurović E, Mikhailidis DP, Mantzoros C. Commentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be based. Metabolism 2020; 109: 154305.
[http://dx.doi.org/10.1016/j.metabol.2020.154305] [PMID: 32645512]
[157]
Parra-Vargas M, Rodriguez-Echevarria R, Jimenez-Chillaron JC. Nutritional approaches for the management of nonalcoholic fatty liver disease: An evidence-based review. Nutrients 2020; 12(12): 3860.
[http://dx.doi.org/10.3390/nu12123860] [PMID: 33348700]
[158]
Lian CY, Zhai ZZ, Li ZF, Wang L. High fat diet-triggered non-alcoholic fatty liver disease: A review of proposed mechanisms. Chem Biol Interact 2020; 330: 109199.
[http://dx.doi.org/10.1016/j.cbi.2020.109199] [PMID: 32805210]
[159]
Davis JN, Lê KA, Walker RW, et al. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr 2010; 92(6): 1522-7.
[http://dx.doi.org/10.3945/ajcn.2010.30185] [PMID: 20962157]
[160]
Schwimmer JB, Ugalde-Nicalo P, Welsh JA, et al. Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys. JAMA 2019; 321(3): 256-65.
[http://dx.doi.org/10.1001/jama.2018.20579] [PMID: 30667502]
[161]
Ramon-Krauel M, Salsberg SL, Ebbeling CB, et al. A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes 2013; 9(3): 252-60.
[http://dx.doi.org/10.1089/chi.2013.0022] [PMID: 23705885]
[162]
Anania C, Perla FM, Olivero F, Pacifico L, Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol 2018; 24(19): 2083-94.
[http://dx.doi.org/10.3748/wjg.v24.i19.2083] [PMID: 29785077]
[163]
Sekkarie A, Welsh JA, Vos MB. Carbohydrates and diet patterns in nonalcoholic fatty liver disease in children and adolescents. Curr Opin Clin Nutr Metab Care 2018; 21(4): 283-8.
[http://dx.doi.org/10.1097/MCO.0000000000000476] [PMID: 29781841]
[164]
Mosca A, Nobili V, De Vito R, et al. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. J Hepatol 2017; 66(5): 1031-6.
[http://dx.doi.org/10.1016/j.jhep.2016.12.025] [PMID: 28214020]
[165]
DiStefano JK, Shaibi GQ. The relationship between excessive dietary fructose consumption and paediatric fatty liver disease. Pediatr Obes 2021; 16(6): e12759.
[http://dx.doi.org/10.1111/ijpo.12759] [PMID: 33305889]
[166]
Nobili V, Mosca A, De Vito R, Raponi M, Scorletti E, Byrne CD. Liver zonation in children with non-alcoholic fatty liver disease: Associations with dietary fructose and uric acid concentrations. Liver Int 2018; 38(6): 1102-9.
[http://dx.doi.org/10.1111/liv.13661] [PMID: 29222961]
[167]
Schwarz JM, Noworolski SM, Erkin-Cakmak A, et al. Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology 2017; 153(3): 743-52.
[http://dx.doi.org/10.1053/j.gastro.2017.05.043] [PMID: 28579536]
[168]
Barton M, Barton M. Screening for obesity in children and adolescents: US Preventive Services Task Force recommendation statement. Pediatrics 2010; 125(2): 361-7.
[http://dx.doi.org/10.1542/peds.2009-2037] [PMID: 20083515]
[169]
Reinehr T, Schmidt C, Toschke AM, Andler W. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. Arch Dis Child 2009; 94(6): 437-42.
[http://dx.doi.org/10.1136/adc.2008.143594] [PMID: 19224892]
[170]
Grønbæk H, Lange A, Birkebæk NH, et al. Effect of a 10-week weight loss camp on fatty liver disease and insulin sensitivity in obese Danish children. J Pediatr Gastroenterol Nutr 2012; 54(2): 223-8.
[http://dx.doi.org/10.1097/MPG.0b013e31822cdedf] [PMID: 21760546]
[171]
de Piano A, de Mello MT, Sanches PL, et al. Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents. Eur J Gastroenterol Hepatol 2012; 24(11): 1.
[http://dx.doi.org/10.1097/MEG.0b013e32835793ac] [PMID: 22932160]
[172]
Van Der Heijden GJ, Wang ZJ, Chu Z, et al. Strength exercise improves muscle mass and hepatic insulin sensitivity in obese youth. Med Sci Sports Exerc 2010; 42(11): 1973-80.
[http://dx.doi.org/10.1249/MSS.0b013e3181df16d9] [PMID: 20351587]
[173]
Lee S, Bacha F, Hannon T, Kuk JL, Boesch C, Arslanian S. Effects of aerobic versus resistance exercise without caloric restriction on abdominal fat, intrahepatic lipid, and insulin sensitivity in obese adolescent boys: A randomized, controlled trial. Diabetes 2012; 61(11): 2787-95.
[http://dx.doi.org/10.2337/db12-0214] [PMID: 22751691]
[174]
Lee S, Deldin AR, White D, et al. Aerobic exercise but not resistance exercise reduces intrahepatic lipid content and visceral fat and improves insulin sensitivity in obese adolescent girls: A randomized controlled trial. Am J Physiol Endocrinol Metab 2013; 305(10): E1222-9.
[http://dx.doi.org/10.1152/ajpendo.00285.2013] [PMID: 24045865]
[175]
González-Ruiz K, Ramírez-Vélez R, Correa-Bautista JE, Peterson MD, García-Hermoso A. The effects of exercise on abdominal fat and liver enzymes in pediatric obesity: A systematic review and meta-analysis. Child Obes 2017; 13(4): 272-82.
[http://dx.doi.org/10.1089/chi.2017.0027] [PMID: 28322576]
[176]
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019; 92: 82-97.
[http://dx.doi.org/10.1016/j.metabol.2018.11.014] [PMID: 30502373]
[177]
Nobili V, Manco M, Devito R, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology 2008; 48(1): 119-28.
[http://dx.doi.org/10.1002/hep.22336] [PMID: 18537181]
[178]
Pozzato C, Verduci E, Scaglioni S, et al. Liver fat change in obese children after a 1-year nutrition-behavior intervention. J Pediatr Gastroenterol Nutr 2010; 51(3): 331-5.
[http://dx.doi.org/10.1097/MPG.0b013e3181d70468] [PMID: 20562718]
[179]
Koot BGP, van der Baan-Slootweg OH, Tamminga-Smeulders CLJ, et al. Lifestyle intervention for non-alcoholic fatty liver disease: Prospective cohort study of its efficacy and factors related to improvement. Arch Dis Child 2011; 96(7): 669-74.
[http://dx.doi.org/10.1136/adc.2010.199760] [PMID: 21518734]
[180]
Wang CL, Liang L, Fu JF, et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol 2008; 14(10): 1598-602.
[http://dx.doi.org/10.3748/wjg.14.1598] [PMID: 18330955]
[181]
Utz-Melere M, Targa-Ferreira C, Lessa-Horta B, Epifanio M, Mouzaki M, Mattos AA. Non-alcoholic fatty liver disease in children and adolescents: Lifestyle change - a systematic review and meta-analysis. Ann Hepatol 2018; 17(3): 345-54.
[http://dx.doi.org/10.5604/01.3001.0011.7380] [PMID: 29735796]
[182]
Flisiak-Jackiewicz M, Lebensztejn DM. Update on pathogenesis, diagnostics and therapy of nonalcoholic fatty liver disease in children. Clin Exp Hepatol 2019; 5(1): 11-21.
[http://dx.doi.org/10.5114/ceh.2019.83152] [PMID: 30915402]
[183]
Mameli C, Krakauer JC, Krakauer NY, et al. Effects of a multidisciplinary weight loss intervention in overweight and obese children and adolescents: 11 years of experience. PLoS One 2017; 12(7): e0181095.
[http://dx.doi.org/10.1371/journal.pone.0181095] [PMID: 28704494]
[184]
Sayin FK, Buyukinan M. Sleep duration and media time have a major impact on insulin resistance and metabolic risk factors in obese children and adolescents. Child Obes 2016; 12(4): 272-8.
[http://dx.doi.org/10.1089/chi.2015.0126] [PMID: 26978730]
[185]
Miller AL, Lumeng JC, LeBourgeois MK. Sleep patterns and obesity in childhood. Curr Opin Endocrinol Diabetes Obes 2015; 22(1): 41-7.
[http://dx.doi.org/10.1097/MED.0000000000000125] [PMID: 25517022]
[186]
Mintziori G, Polyzos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opin Pharmacother 2016; 17(14): 1937-46.
[http://dx.doi.org/10.1080/14656566.2016.1225727] [PMID: 27564402]
[187]
Polyzos SA, Kountouras J, Anastasiadis S, Doulberis M, Katsinelos P. Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach? Hepatology 2018; 68(1): 389.
[http://dx.doi.org/10.1002/hep.29897] [PMID: 29601090]
[188]
Attia SL, Softic S, Mouzaki M. Evolving role for pharmacotherapy in NAFLD/NASH. Clin Transl Sci 2021; 14(1): 11-9.
[http://dx.doi.org/10.1111/cts.12839] [PMID: 32583961]
[189]
Pilitsi E, Farr OM, Polyzos SA, et al. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism 2019; 92: 170-92.
[http://dx.doi.org/10.1016/j.metabol.2018.10.010] [PMID: 30391259]
[190]
Schwimmer JB, Middleton MS, Deutsch R, Lavine JE. A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005; 21(7): 871-9.
[http://dx.doi.org/10.1111/j.1365-2036.2005.02420.x] [PMID: 15801922]
[191]
Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: The TONIC randomized controlled trial. JAMA 2011; 305(16): 1659-68.
[http://dx.doi.org/10.1001/jama.2011.520] [PMID: 21521847]
[192]
Abdel-Maboud M, Menshawy A, Menshawy E, Emara A, Alshandidy M, Eid M. The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression. Therap Adv Gastroenterol 2020; 13: 1756284820974917.
[http://dx.doi.org/10.1177/1756284820974917] [PMID: 33335561]
[193]
Lin M, Zeng H, Deng G, Lei J, Li J. Vitamin E in paediatric non-alcoholic fatty liver disease: A meta-analysis. Clin Res Hepatol Gastroenterol 2021; 45(3): 101530.
[http://dx.doi.org/10.1016/j.clinre.2020.08.008] [PMID: 33272889]
[194]
Black LJ, Jacoby P, She Ping-Delfos WC, et al. Low serum 25-hydroxyvitamin D concentrations associate with non-alcoholic fatty liver disease in adolescents independent of adiposity. J Gastroenterol Hepatol 2014; 29(6): 1215-22.
[http://dx.doi.org/10.1111/jgh.12541] [PMID: 24611991]
[195]
Hourigan SK, Abrams S, Yates K, et al. Relation between vitamin D status and nonalcoholic fatty liver disease in children. J Pediatr Gastroenterol Nutr 2015; 60(3): 396-404.
[http://dx.doi.org/10.1097/MPG.0000000000000598] [PMID: 25710716]
[196]
Nobili V, Giorgio V, Liccardo D, et al. Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur J Endocrinol 2014; 170(4): 547-53.
[http://dx.doi.org/10.1530/EJE-13-0609] [PMID: 24412930]
[197]
El Amrousy D, Abdelhai D, Shawky D. Vitamin D and nonalcoholic fatty liver disease in children: A randomized controlled clinical trial. Eur J Pediatr 2022; 181(2): 579-86.
[http://dx.doi.org/10.1007/s00431-021-04243-4] [PMID: 34459959]
[198]
Harlow KE, Africa JA, Wells A, et al. Clinically actionable hypercholesterolemia and hypertriglyceridemia in children with nonalcoholic fatty liver disease. J Pediatr 2018; 198: 76-83.e2.
[http://dx.doi.org/10.1016/j.jpeds.2018.02.038] [PMID: 29661561]
[199]
Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An expert panel statement. Metabolism 2017; 71: 17-32.
[http://dx.doi.org/10.1016/j.metabol.2017.02.014] [PMID: 28521870]
[200]
Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: Double-blind randomised controlled clinical trial. Arch Dis Child 2011; 96(4): 350-3.
[http://dx.doi.org/10.1136/adc.2010.192401] [PMID: 21233083]
[201]
Nobili V, Bedogni G, Donati B, Alisi A, Valenti L. The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. J Med Food 2013; 16(10): 957-60.
[http://dx.doi.org/10.1089/jmf.2013.0043] [PMID: 24074360]
[202]
Zöhrer E, Alisi A, Jahnel J, et al. Efficacy of docosahexaenoic acid–choline–vitamin E in paediatric NASH: A randomized controlled clinical trial. Appl Physiol Nutr Metab 2017; 42(9): 948-54.
[http://dx.doi.org/10.1139/apnm-2016-0689] [PMID: 28511023]
[203]
Della Corte C, Carpino G, De Vito R, et al. Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency: Results from a single centre trial. PLoS One 2016; 11(12): e0168216.
[http://dx.doi.org/10.1371/journal.pone.0168216] [PMID: 27977757]
[204]
Janczyk W, Lebensztejn D. , Wierzbicka-Rucińska A, et al. Omega-3 fatty acids therapy in children with nonalcoholic fatty liver disease: A randomized controlled trial. J Pediatr 2015; 166: 1358-63.
[205]
Dasarathy S, Dasarathy J, Khiyami A, et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2015; 49(2): 137-44.
[http://dx.doi.org/10.1097/MCG.0000000000000099] [PMID: 24583757]
[206]
Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019; 76(8): 1541-58.
[http://dx.doi.org/10.1007/s00018-019-03011-w] [PMID: 30683985]
[207]
Lavekar AS, Raje DV, Lavekar AAA, Lavekar A. Role of probiotics in the treatment of nonalcoholic fatty liver disease: A meta-analysis. Euroasian J Hepatogastroenterol 2017; 7(2): 130-7.
[http://dx.doi.org/10.5005/jp-journals-10018-1233] [PMID: 29201794]
[208]
Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 2011; 52(6): 740-3.
[http://dx.doi.org/10.1097/MPG.0b013e31821f9b85] [PMID: 21505361]
[209]
Polyzos SA, Kang ES, Boutari C, Rhee EJ, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020; 111: 154203.
[http://dx.doi.org/10.1016/j.metabol.2020.154203] [PMID: 32151660]
[210]
Page LC, Freemark M. Role of GLP-1 receptor agonists in pediatric obesity: Benefits, risks, and approaches to patient selection. Curr Obes Rep 2020; 9(4): 391-401.
[http://dx.doi.org/10.1007/s13679-020-00409-7] [PMID: 33085056]
[211]
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Semaglutide, lipid-lowering drugs, and NAFLD. Lancet Diabetes Endocrinol 2017; 5(5): 329-30.
[http://dx.doi.org/10.1016/S2213-8587(17)30109-2] [PMID: 28434490]
[212]
Janez A, Muzurovic E, Stoian AP, et al. Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group. Int J Cardiol 2022; 365: 8-18.
[http://dx.doi.org/10.1016/j.ijcard.2022.07.017] [PMID: 35905827]
[213]
Muzurović E, Mikhailidis DP. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile. Expert Opin Pharmacother 2020; 21(17): 2125-35.
[http://dx.doi.org/10.1080/14656566.2020.1795132] [PMID: 32697112]
[214]
Muzurović E, Dragnić S, Medenica S, Smolović B, Bulajić P, Mikhailidis DP. Weight-centric pharmacological management of type 2 diabetes mellitus – An essential component of cardiovascular disease prevention. J Diabetes Complications 2020; 34(8): 107619.
[http://dx.doi.org/10.1016/j.jdiacomp.2020.107619] [PMID: 32499116]
[215]
Schwimmer JB, Lavine JE, Wilson LA, et al. In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores. Gastroenterology 2016; 151(6): 1141-1154.e9.
[http://dx.doi.org/10.1053/j.gastro.2016.08.027] [PMID: 27569726]
[216]
Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut 2017; 66(1): 180-90.
[http://dx.doi.org/10.1136/gutjnl-2016-312431] [PMID: 27646933]
[217]
Polyzos SA, Mantzoros CS. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. Metabolism 2016; 65(9): 1297-306.
[http://dx.doi.org/10.1016/j.metabol.2016.05.013] [PMID: 27506737]
[218]
Nobili V, Vajro P, Dezsofi A, et al. Indications and limitations of bariatric intervention in severely obese children and adolescents with and without nonalcoholic steatohepatitis: ESPGHAN hepatology committee position statement. J Pediatr Gastroenterol Nutr 2015; 60(4): 550-61.
[http://dx.doi.org/10.1097/MPG.0000000000000715] [PMID: 25591123]
[219]
Nguyen V, Li J, Gan J, et al. Outcomes following serial intragastric balloon therapy for obesity and nonalcoholic fatty liver disease in a single centre. Can J Gastroenterol Hepatol 2017; 2017: 4697194.
[http://dx.doi.org/10.1155/2017/4697194] [PMID: 29441342]
[220]
Claudia Gollisch KS, Raddatz D. Endoscopic intragastric balloon: A gimmick or a viable option for obesity? Ann Transl Med 2020; 8 (Suppl. 1): S8.
[http://dx.doi.org/10.21037/atm.2019.09.67] [PMID: 32309412]
[221]
Lamoshi A, Chernoguz A, Harmon CM, Helmrath M. Complications of bariatric surgery in adolescents. Semin Pediatr Surg 2020; 29(1): 150888.
[http://dx.doi.org/10.1016/j.sempedsurg.2020.150888] [PMID: 32238287]
[222]
Manco M, Mosca A, De Peppo F, et al. The benefit of sleeve gastrectomy in obese adolescents on nonalcoholic steatohepatitis and hepatic fibrosis. J Pediatr 2017; 180: 31-37.e2.
[http://dx.doi.org/10.1016/j.jpeds.2016.08.101] [PMID: 27697327]
[223]
Nobili V, Carpino G, De Peppo F, et al. Laparoscopic sleeve gastrectomy improves nonalcoholic fatty liver disease–related liver damage in adolescents by reshaping cellular interactions and hepatic adipocytokine production. J Pediatr 2018; 194: 100-108.e3.
[http://dx.doi.org/10.1016/j.jpeds.2017.10.036] [PMID: 29198531]
[224]
Franchitto A, Carpino G, Alisi A, et al. The contribution of the adipose tissue-liver axis in pediatric patients with nonalcoholic fatty liver disease after laparoscopic sleeve gastrectomy. J Pediatr 2020; 216: 117-127.e2.
[http://dx.doi.org/10.1016/j.jpeds.2019.07.037] [PMID: 31526528]
[225]
Michalsky M, Reichard K, Inge T, Pratt J, Lenders C. ASMBS pediatric committee best practice guidelines. Surg Obes Relat Dis 2012; 8(1): 1-7.
[http://dx.doi.org/10.1016/j.soard.2011.09.009] [PMID: 22030146]
[226]
Pratt JSA, Browne A, Browne NT, et al. ASMBS pediatric metabolic and bariatric surgery guidelines, 2018. Surg Obes Relat Dis 2018; 14(7): 882-901.
[http://dx.doi.org/10.1016/j.soard.2018.03.019] [PMID: 30077361]
[227]
Mikolasevic I, Filipec-Kanizaj T, Mijic M, et al. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? World J Gastroenterol 2018; 24(14): 1491-506.
[http://dx.doi.org/10.3748/wjg.v24.i14.1491] [PMID: 29662288]
[228]
Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015; 148(3): 547-55.
[http://dx.doi.org/10.1053/j.gastro.2014.11.039] [PMID: 25461851]
[229]
Cananzi M, Vajro P, Rela M, Dhawan A. NAFLD and liver transplantation in children—working group report from the ILTS single topic conference on NAFLD. Transplantation 2019; 103(1): 68-70.
[http://dx.doi.org/10.1097/TP.0000000000002490] [PMID: 30335699]
[230]
Saeed N, Glass L, Sharma P, Shannon C, Sonnenday CJ, Tincopa MA. Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: Systematic review and meta-analysis. Transplantation 2019; 103(11): e345-54.
[http://dx.doi.org/10.1097/TP.0000000000002916] [PMID: 31415032]
[231]
Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol 2017; 23(36): 6549-70.
[http://dx.doi.org/10.3748/wjg.v23.i36.6549] [PMID: 29085205]
[232]
Crespo M, Lappe S, Feldstein AE, Alkhouri N. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism 2016; 65(8): 1161-71.
[http://dx.doi.org/10.1016/j.metabol.2016.01.008] [PMID: 26961580]
[233]
Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009; 137(3): 865-72.
[http://dx.doi.org/10.1053/j.gastro.2009.06.005] [PMID: 19524579]
[234]
Maffeis C, Banzato C, Rigotti F, et al. Biochemical parameters and anthropometry predict NAFLD in obese children. J Pediatr Gastroenterol Nutr 2011; 53(6): 590-3.
[http://dx.doi.org/10.1097/MPG.0b013e31822960be] [PMID: 21697744]
[235]
Barritt AS IV, Gitlin N, Klein S, et al. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Contemp Clin Trials 2017; 61: 33-8.
[http://dx.doi.org/10.1016/j.cct.2017.07.015] [PMID: 28735109]
[236]
Mann JP, Vreugdenhil A, Socha P, et al. European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. Contemp Clin Trials 2018; 75: 67-71.
[http://dx.doi.org/10.1016/j.cct.2018.11.003] [PMID: 30408605]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy